桑耶青作为IBD和CRC潜在治疗候选者的潜在作用和有效成分
Chaoying Chen1, Lin Chen1, Weifeng Zheng1
1Department of Gastroenterology, The Fourth Affiliated Hospital ZheJiang University School of Medicine, Yiwu, Zhejiang, 322000, People's Republic of China.
OncoTargets and therapy
|July 14, 2025
概括
这项研究探讨了炎症性肠病 (IBD) 和结直肠癌 (CRC) 的分子机制,突出了药用草药桑叶青在治疗这些疾病方面的潜力.
科学领域:
- 胃肠道学和瘤学
- 药理学和草药医学 药理学和草药医学
背景情况:
- 炎症性肠病 (IBD),包括克罗恩氏病和性结肠炎,显著增加结直肠癌 (CRC) 的风险.
- 患有IBD和CRC的患者经常出现重叠的症状,如腹,直肠出血和疲劳,使诊断和治疗复杂化.
- 慢性胰腺癌是一种与慢性IBD相关的流行和严重恶性瘤.
研究的目的:
- 阐明IBD和CRC背后的分子机制.
- 审查传统药草桑叶青的治疗潜力,用于治疗IBD和CRC.
- 强调了解肠炎和肠癌病因的重要性,以制定预防和治疗策略.
主要方法:
- 文献综述总结了IBD和CRC的分子机制.
- 分析Sanyeqing记录的药理性质,包括抗瘤和抗炎作用.
- 综合有关IBD,CRC和Sanyeqing潜在临床应用的当前知识.
主要成果:
- 确定了涉及IBD和CRC病变发生的共享分子通路.
- 突出了Sanyeqing的多方面的药用特性,与IBD和CRC治疗有关.
- 建立了桑耶青在管理这些复杂疾病中的作用的理论框架.
结论:
- 桑耶因其抗炎和抗瘤特性而显示出作为IBD和CRC的补充治疗剂的前景.
- 对Sanyeqing的分子机制和临床疗效的进一步研究是有必要的.
- 研究肠炎和肠癌的病因对于推进治疗和预防策略至关重要.
相关概念视频
Drugs for Treatment of Diarrhea-Predominant IBS
303
Diarrhea-predominant irritable bowel syndrome (IBS-D) is a subtype of IBS characterized primarily by frequent, loose, or watery stools, abdominal pain, and abdominal discomfort. Therapeutic approaches to managing IBS-D include dietary changes, stress management techniques, and pharmaceutical interventions.
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
303
Drugs for Treatment of Ulcerative Colitis in IBD
239
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
239
Inflammatory Bowel Disease III: Diagnostic Studies and Management I-Nutritional Therapy
426
Various diagnostic tests are employed in the diagnostic process for Inflammatory Bowel Disease (IBD), particularly to differentiate between Crohn's disease and ulcerative colitis.
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...
426
Inflammatory Bowel Disease IV: Pharmacological Management
198
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
198
Drugs for Treatment of Constipation-Predominant IBS
347
Pharmacological therapies for IBS-C are designed to alleviate abdominal discomfort and enhance bowel function. In patients with IBS-C, fiber supplements may help soften stools and decrease straining, but may also lead to increased gas production and bloating. Osmotic laxatives like milk of magnesia are frequently used to soften stools and increase stool frequency in IBS-C patients. In addition, two drugs approved for use in severe IBS-C adult cases are linaclotide (Linzess) and lubiprostone...
347
Irritable Bowel Syndrome III: Medical and Nursing Management
311
Managing Irritable Bowel Syndrome (IBS) involves a multifaceted approach, including lifestyle modifications, dietary changes, and medication.
311


